Zortress
® (
everolimus) is a prescription medication approved to prevent kidney transplant rejection, which occurs when the immune system identifies the new kidney as a foreign object and attacks it. Zortress is in a group of medicines called kinase inhibitors. It is always used in combination with other anti-rejection medications.
Zortress contains everolimus, which is also the active ingredient in
Afinitor®. Afinitor is available in higher-strength tablets and is approved to treat certain types of cancers and tumors.
Who Makes This Medication?
Zortress is made by Novartis Pharma Stein AG for Novartis Pharmaceuticals Corporation.
Zortress works to prevent transplant rejection by weakening the immune system.
When certain white blood cells, called lymphocytes, encounter foreign material, they change into an active form and begin to rapidly reproduce so there are more of them available to fight the invading substance. Zortress blocks the activation and rapid reproduction of these lymphocytes, thus preventing an immune response against the newly transplanted kidney.
HealthSavvy Sign In
|
